231 related articles for article (PubMed ID: 29589598)
1. Erratum: Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum].
Breast Cancer (Dove Med Press); 2018; 10():51. PubMed ID: 29589598
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum.
Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
[TBL] [Abstract][Full Text] [Related]
3. Erratum: Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum].
Int J Womens Health; 2015; 7():403. PubMed ID: 25960676
[TBL] [Abstract][Full Text] [Related]
4. Erratum: Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum].
Ther Clin Risk Manag; 2016; 12():1083. PubMed ID: 27462161
[TBL] [Abstract][Full Text] [Related]
5. Erratum: Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [Corrigendum].
J Pain Res; 2018; 11():213. PubMed ID: 29406534
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum].
Clinicoecon Outcomes Res; 2017; 9():75. PubMed ID: 28174493
[TBL] [Abstract][Full Text] [Related]
7. Erratum: Primary neuroendocrine breast carcinomas: a retrospective analysis and review of literature [Corrigendum].
Onco Targets Ther; 2017; 10():1707. PubMed ID: 28356757
[TBL] [Abstract][Full Text] [Related]
8. Erratum: BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum].
Breast Cancer (Dove Med Press); 2015; 7():163. PubMed ID: 26170717
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Effect of first-line endocrine therapy in patients with hormone-sensitive advanced breast cancer: a network meta-analysis [Corrigendum].
Onco Targets Ther; 2018; 11():4449. PubMed ID: 30104886
[TBL] [Abstract][Full Text] [Related]
10. Erratum: Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum].
Clin Interv Aging; 2016; 11():775. PubMed ID: 27358559
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum.
Sun XH; Yu HZ; Yang MM; Yang YM; Dang ZM
J Cachexia Sarcopenia Muscle; 2015 Jun; 6(2):192. PubMed ID: 26140254
[TBL] [Abstract][Full Text] [Related]
12. Erratum: corrigendum.
Clin Ophthalmol; 2011; 5():1557. PubMed ID: 22125401
[TBL] [Abstract][Full Text] [Related]
13. Erratum: PUMA mediates the anti-cancer effect of osimertinib in colon cancer cells [Corrigendum].
Onco Targets Ther; 2018; 11():687. PubMed ID: 29443312
[TBL] [Abstract][Full Text] [Related]
14. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date.
Criscitiello C; Viale G; Curigliano G; Goldhirsch A
Breast Cancer (Dove Med Press); 2018; 10():23-29. PubMed ID: 29430197
[TBL] [Abstract][Full Text] [Related]
15. Erratum: Integrating complementary/alternative medicine into primary care: evaluating the evidence and appropriate implementation [Corrigendum].
Int J Gen Med; 2016; 9():19. PubMed ID: 26929660
[TBL] [Abstract][Full Text] [Related]
16. Erratum: B-cell-specific Moloney murine leukemia virus integration site 1: potential stratification factor and therapeutic target for epithelial ovarian cancer [Corrigendum
Onco Targets Ther; 2017; 10():2323. PubMed ID: 28490890
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Fibronectin 1 promotes migration and invasion of papillary thyroid cancer and predicts papillary thyroid cancer lymph node metastasis [Corrigendum].
Onco Targets Ther; 2017; 10():2737-2738. PubMed ID: 28603422
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Delivery of curcumin by directed self-assembled micelles enhances therapeutic treatment of non-small-cell lung cancer [Corrigendum].
Int J Nanomedicine; 2017; 12():8375-8376. PubMed ID: 29200849
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum].
Cancer Manag Res; 2018; 10():613. PubMed ID: 29630065
[TBL] [Abstract][Full Text] [Related]
20. Erratum: Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer [Corrigendum].
Int J Nanomedicine; 2017; 12():4661. PubMed ID: 28721042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
